Board of Directors

Petri Salonen (born 1958) serves as the Chairman of the Board of Directors of Delfoi Ltd and as a member of the Board of Directors of Futudent Oy. In addition, he serves as Sales Director at JAS Partners Oy.

Previously, Mr. Salonen has been in the board and in the management of various companies. He holds a Master of Science degree in Shipbuilding Technology, Naval Architecture and Marine Engineering from Aalto University.

Petri Salonen is dependent of the Company as he has had a consultancy agreement with the Company and recei-ves salary. Further, he has been a member of the Board for more than 10 years.

Catherine Calarco (born 1960) is a global executive in AI, Healthcare, and SaaS. She serves as a Board Advisor for Astia and Nerbio, and an Executive Consultant in Go-To-Market strategy, growth acceleration, and digital trans-formation.

She is a member of the Exceptional Women’s Alliance and Avante Capital Women’s Operator Network. Previously, she was VP at Automation Anywhere and a Board Member at MIT CNC. She holds a Bachelor’s degree in Biology and Chemistry (California State University) and an MBA from MIT Sloan School of Management.

Catherine is independent of both Optomed and its major shareholders.

Seppo Mäkinen (born 1952) serves as the Chairman of the Board of Klinik Healthcare Solutions Oy and as a member of the Board of Directors of Ginolis Oy.

Previously, Mr Mäkinen has been a member or a chairman of board of directors and management positions of various companies globally. He holds a Master of Science degree in Physical Chemistry from the University of Jyväs-kylä.

He is independent of both Optomed and its major shareholders.

Reijo Tauriainen (born 1956) serves as the Chairman of the Board of Director of Pohjolan Rakennustaito Oy.

Previously, Mr. Tauriainen has been a CFO, a board member or board chair in various public and private companies. He holds a Master of Science degree in Economics from the University of Oulu.

He is independent of both Optomed and its major shareholders.

Ty Lee (born 1970) serves as the Group President, North America of Demant as well as the Chair of the Board of Birdsong Hearing Benefits LLC.

He holds a Master of Business Administration degree (University of California, Berkeley, Haas School of Business), a Master of Liberal Arts degree (Harvard University), and a Master of Science degree (Northwestern University).

He is independent of both Optomed and its major shareholders.

Leana Wen (born 1983) is a practicing physician and healthcare executive. She serves on the board of directors and audit committees of Glaukos Corporation and UroGen Pharma; at UroGen, she also chairs the nominations and corporate Governance committee.

Additionally, she chairs the advisory board of the Behavioral Health Group and advises venture-backed health innovation companies.

Her previous roles include serving as the health commissioner for Baltimore and medical analyst for CNN; her recognitions include being Modern Healthcare’s Top 50 Physician-Executives and TIME magazine’s 100 Most Influential People. She holds a B.S. from California State University, Los Angeles, an M.D. from Washington University School of Medicine and two M.Sc.s from the University of Oxford, where she was a Rhodes Scholar.

She is independent of both Optomed and its major shareholders.

Sameer Badlani (born 1974) is a board director and C suite executive with more than 20 years of experience guiding complex, highly regulated organizations through strategic growth, transformation, and risk oversight.

He currently serves as Executive Vice President, Chief Strategy Officer, and Chief Digital Officer at Fairview Health Services, a $9 billion integrated health system.

Dr. Badlani currently chairs the board of Fairview Pharmacy Services and serves on the boards of Q Rounds (seed stage startup), and American Public Media Group/Minnesota Public Radio (non-profit) where he serves on Strategy, Finance, Audit, and Risk board committees. He holds an M.D. from Delhi University and is a graduate of the Harvard Business School’s Advanced Management Program.

He is independent of both Optomed and its major shareholders.

Kristiina Leppänen is an experienced Chief Financial Officer with extensive international experience in industrial and technology companies as well as group-level financial leadership.

She has held several Group CFO  positions at companies including HeadFirst Global, Infinigate Group, GPV, Cavotec, GS‑Hydro Group and Marioff Corporation. In these roles, she has been responsible for financial management, financing, investor relations, as well as projects related to corporate transactions and international growth.

Ms. Leppänen also has strong board experience. She serves as a Board Member of Multitude Bank and acts as Chair of the Audit Committee and member of the Risk Committee. At Optomed, she is also a member of the Audit Committee.

She holds an MBA degree as well as a Bachelor’s degree in International Finance (BBA) from Aalto University and the University of South Carolina.

Kristiina Leppänen is independent of the Company and its significant shareholders and is a Finnish citizen.